Despite steep costs, payments for new cancer drugs make economic sense

被引:0
|
作者
Frank R Lichtenberg
机构
[1] Frank R. Lichtenberg is the Courtney C. Brown Professor of Business at Columbia University Graduate School of Business in New York and a research associate at the National Bureau of Economic Research in Cambridge,
[2] Massachusetts. His research has been supported by pharmaceutical and device companies as well as by government and nonprofit organizations.,undefined
来源
Nature Medicine | 2011年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cancer drugs have become more expensive over the past few years, leading many people to question whether the treatments are really worth their high costs. But despite the sticker shock, cancer medicines have provided good value for money.
引用
收藏
页码:244 / 244
相关论文
共 21 条
  • [21] Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs
    Berry, Scott R.
    Bell, Chaim M.
    Ubel, Peter A.
    Evans, William K.
    Nadler, Eric
    Strevel, Elizabeth L.
    Neumann, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4149 - 4153